06:20 AM EDT, 10/30/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our opinion on GSK to Buy from Hold and revise our target price to USD53 from USD40 following strong Q3 results and a guidance upgrade, which sits at the upper end of the peer range, reflecting better-than-expected execution. Our target price implies a 2026 P/E of 10.7x, higher than its three-year average of 9.3x, reflecting improving execution and the growth opportunity from Specialty Medicines segment. We adjust our EPADS estimates to GBP3.40 from GBP3.30 for 2025 and to GBP3.76 from GBP3.70 for 2026 to account for the guidance upgrade. Overall, we are positive on Specialty Medicines on the back of continued demand and new launches. The recent approval of Blenrep, despite being narrower than initially hoped, remains a positive outcome in our view, following the FDA advisory setback in July that pressured the share price. These are offset by Vaccines weakness, the key HIV treatment trial delay, and execution risks.